WHIPPANY, N.J., May 29, 2019 /PRNewswire/ -- Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for Aliqopa™ (copanlisib) for the treatment of adult patients with relapsed marginal zone lymphoma (MZL) who have received at least...
from PR Newswire: https://prn.to/2JJ4b2z
No comments:
Post a Comment